These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17310793)

  • 1. [Akatinol memantine in the therapy of cognitive disorders in Parkinson's disease].
    Puzin MN; Krivonos OV; Kozhevnikova ZhV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2007; 107(1):26-9. PubMed ID: 17310793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson's disease complicated by dementia.
    Litvinenko IV; Odinak MM; Mogil'naya VI; Perstnev SV
    Neurosci Behav Physiol; 2010 Feb; 40(2):149-55. PubMed ID: 20033305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Memantine (akatinol) therapy of cognitive impairment in Parkinson's disease complicated by dementia].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Perstenev SV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(10):37-42. PubMed ID: 19008850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of akatinol memantine in moderate cognitive impairments.
    Levin OS; Yunishchenko NA; Dudarova MA
    Neurosci Behav Physiol; 2010 Oct; 40(8):926-33. PubMed ID: 20683775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Akatinol memantine in patients with vascular cognitive disorders].
    Gudkova AA; Sorokina IB; Iakovlev AA; Guliaeva NV; Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):37-40. PubMed ID: 21311485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
    Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T
    J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson's disease].
    Li W; Zhao JH; Sun SG; Zhang JW; Suo AQ; Ma MM
    Zhonghua Yi Xue Za Zhi; 2011 Feb; 91(5):301-3. PubMed ID: 21419002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine and reduced time with dyskinesia in Parkinson's Disease.
    Wictorin K; Widner H
    Acta Neurol Scand; 2016 May; 133(5):355-60. PubMed ID: 26234336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of acatinol memantine in mild cognitive disorder].
    Levin OS; Iunishchenko NA; Dudarova MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(7):36-42. PubMed ID: 19672236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of memantine in Parkinson's disease with dementia].
    Levin OS; Batukaeva LA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(12):16-23. PubMed ID: 19156121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An impact of pronoran on cognitive and affective disorders in Parkinson's disease].
    Pilipovich AA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):41-7. PubMed ID: 15875942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
    Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
    Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
    Merello M; Nouzeilles MI; Cammarota A; Leiguarda R
    Clin Neuropharmacol; 1999; 22(5):273-6. PubMed ID: 10516877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure].
    Lökk J
    Lakartidningen; 2004 Jun; 101(23):2003-6. PubMed ID: 15232837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Articulation disorders and duration, severity and L-dopa dosage in idiopathic Parkinson's disease.
    Pawlukowska W; Gołąb-Janowska M; Safranow K; Rotter I; Amernik K; Honczarenko K; Nowacki P
    Neurol Neurochir Pol; 2015; 49(5):302-6. PubMed ID: 26377981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled trial of memantine in dementia associated with Parkinson's disease.
    Leroi I; Overshott R; Byrne EJ; Daniel E; Burns A
    Mov Disord; 2009 Jun; 24(8):1217-21. PubMed ID: 19370737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies.
    Wesnes KA; Aarsland D; Ballard C; Londos E
    Int J Geriatr Psychiatry; 2015 Jan; 30(1):46-54. PubMed ID: 24737460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial.
    Schulz JB; Rainer M; Klünemann HH; Kurz A; Wolf S; Sternberg K; Tennigkeit F
    J Alzheimers Dis; 2011; 25(3):463-75. PubMed ID: 21471647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.